Meeting Homepage
Speaker Presentations
Speaker Bios
Meeting Committee
Meeting Program:
Schedule-at-a-Glance
Workshops-at-a-Glance
Technology Showcase
Add-on Seminars
Plenary Sessions
Workshops
PDS Workshops
CLE
Additional Events:
Networking Events
Tech Fair
Tours
Sponsors:
Meeting Sponsors
Sponsorship Opportunities
Miscellaneous Info:
Hotel
Weather and Dress
|
Speaker Biographies
Louis P. Berneman
Lou Berneman is an experienced intelle
ctual property licensing
and business development executive. He has founded and financed entrepreneurial
ventures and has built and managed a university technology transfer program.
Currently, Lou is the Principal of Texelerate, a development-stage
intellectual property trading company.. Since September 2005, Texelerate
has been functioning as a consultancy specializing in academic-industry technology
commercialization. Texelerate clients include academic research institutions
and teaching hospitals, companies and law firms. Berneman is a consultant
to and member of the Strategic Advisory Board of the Paul Capital Partners
Royalty Healthcare Funds.
Berneman is a Past President of the Association of University
Technology Managers (AUTM) and a former Vice President and Trustee of the
Licensing Executives Society (LES USA & Canada). He has served
as a member of the Board of the Pennsylvania Biotechnology Association, Greater
Philadelphia Venture Group and the LES Foundation. Dr. Berneman is the
2005 recipient of the LES Barnes Mentoring Award and a 2003 recipient of an
Award of Excellence from the Association of University Research Parks.
From 1995-2005, Dr. Berneman was Managing Director of the
Center for Technology Transfer (CTT) at the University of Pennsylvania. Under
his leadership, CTT became one of the most productive university technology
licensing offices in the world:
- filing more than 1500
patents,
- consummating more than
600 option/license agreements,
- launching more than
80 new start up ventures, and
- generating more than
$100 million in license income.
From 1989-1995, Berneman was Director, Licensing and Business
Development at Virginia's Center for Innovative Technology. From 1984-1989,
he founded and served as President and CEO of Biotherapeutics, Inc., a provider
of cancer biotherapy services. He also helped found and served as a Director
of Innotech, Inc., an ophthalmic manufacturing system. From 1982-1984, he
was VP of Marketing and Sales of Immuno-Modulators Laboratories, Inc., an
emerging biopharmaceuticals company. From 1976-1982, he was Assistant Professor
of Education at University of Houston.
Dr. Berneman holds a baccalaureate degree in history from
the Pennsylvania State University, a teaching credential from University of
California at Santa Barbara, and masters and doctoral degrees in education
from Teachers College, Columbia University.
[back to top]
Kris Ann Betres, J.D.
Kris Betres has been a Licensing Manager at the office of Corporate
Sponsored Research & Licensing at Massachusetts General Hospital since
May 2005. Her primary responsibilities include managing the patent,
licensing and research portfolios for the Wellman Center for Photomedicine
and the Transplantation Biology Research Center. Before joining CSR&L,
Kris worked in the legal division at Wyeth Pharmaceuticals. She was previously
affiliated with CSR&L at Brigham and Women's Hospital (1997-2001). Kris
received her J.D. from Boston University with a concentration in Intellectual
Property law and has been admitted to the Massachusetts bar. She received
her B.A. in Biology and in Psychology from Colby College.
[back to top]
Mark G. Bloom, Esq.
Mark is currently Vice President of Business Success Strategists,
LLC.
Mark was formerly Associate GC and Chief IP Counsel, CCF Innovations of Cleveland
Clinic. Mark earned a BS from The Ohio State University, a JD from Franklin
Pierce Law Center, is a member of numerous state bars, courts, and professional
organizations, and is a Registered Patent Attorney.
Before attending law school, Mark worked in sales for the pharmaceutical
and medical device industries.
Mark is currently a member of the Editorial Advisory Board of the AUTM Journal
and the Editorial Board of the AIPLA Quarterly Journal and has served as a
member of the "Expert Group on Best Practice Guidelines for the
Licensing of Genetic Inventions " for the Organization for Economic
Co-operation and Development. Mark serves on the Executive Committee
of the LES Healthcare Sector and is Co-Chair of the LES Joint Biomedical Device
Committee.
[back to top]
Craig Christianson
The Wisconsin Alumni Research Foundation ("WARF")
pioneered university technology transfer over 80 years ago. Instrumental
in the formation and passing of the Bayh-Dole Act in 1980, WARF in recent
history has remained a leader in invention disclosures, patents, and licensing
revenue as over 300 universities participate in patent and licensing
activities.
At the University of Wisconsin during the late 1990's Dr. James Thomson first
successfully cultured in vitro primate and then human embryonic stem cells. WARF
was thrust in the position of facilitating the continuation and expansion
of this
research in the context of a great public research university, broadly and
responsibly licensing this significant platform technology discovery, and
leveraging private resources to distribute cells, provide supporting education,
and help shape public policy through lobbying and outreach efforts.
Now at the halfway point of the patent life, we pause to reflect on the results
of Wisconsin's efforts and look forward to what the next 10 years might bring
with regard to emerging markets and commercialization related to this remarkable
technology.
[back to top]
Dr. Teresa Colella
Dr. Teresa Colella is a Technology Manger at the Applied Physics Laboratory.
Previously, she worked for over four years as a Registered Patent Agent at
Sterne, Kessler, Goldstein and Fox. Dr. Colella carried out post-doctoral
research at Johns Hopkins School of Public Health, obtained her Ph.D. in Microbiology/Immunology
at the University of Virginia, and her B.A. from Wellesley College. She
is an MBA candidate at Loyola College.
[back to top]
Trung Do
Trung is Executive Director of Business Development at Partners HealthCare, where
he has overall responsibility for developing and managing strategic alliances
with industry, and facilitating the marketing of intellectual property
from Partners hospitals.
Trung's background includes more than ten years experience in business
development, management and analytical consulting, product development and
strategic operational functions. Prior to Partners, Trung served
as the Director of Operations at PharMetrics, a venture-backed start-up providing health
care market insights to the pharmaceutical, biotech, medical device, and health
plan sectors of the market. He began his career in health care and life
sciences as a consultant with Arthur Andersen and Boston Biomedical Consultants.
[back to top]
David J. Dykeman
David J. Dykeman is a registered patent attorney and shareholder
in the Boston office of international law firm Greenberg Traurig LLP. With
over a decade of experience in patents, intellectual property, and licensing,
his practice focuses on securing worldwide intellectual property protection
and related business strategy for high tech clients, with an emphasis on medical
devices, nanotechnology, information technology, and life sciences.
David provides strategic patent portfolio development and intellectual property
advice for clients including major research institutions, multi-national corporations,
and start-up companies. He also performs patent due diligence to assess patent
portfolios for venture capital investment, mergers and acquisitions, and licensing
opportunities.
David had been selected as a Massachusetts Super Lawyer Rising Star by Boston
Magazine for two consecutive years. He is a frequent conference speaker and
published author on intellectual property law. His articles have appeared in
Intellectual Property Today magazine, Boston Business Journal, Mass High Tech
journal, Massachusetts Medical Law Report, Massachusetts Lawyers Weekly and
Wiley Intellectual Property Law Update. David received his law degree from the
University of Wisconsin Law School, and his Bachelor of Science degree in mechanical
engineering from Cornell University.
[back to top]
Thomas J. Engellenner
Thomas J. Engellenner is a partner and a co-chair of Nutter's Intellectual
Property and Life Sciences practice groups. His practice includes patents,
trademarks, copyrights, licensing, and litigation. He has particular expertise
in the patenting and licensing of biotechnology, pharmaceuticals, and medical
devices. Tom began his career as a trial attorney for the U.S. Environmental
Protection Agency. Prior to entering the private practice of law, he was an
associate patent counsel at the Massachusetts Institute of Technology. Active
in the bar, Tom is a member of the American, Massachusetts, and Boston Bar
Associations, the American Intellectual Property Law Association, and served
as president of the Boston Patent Law Association in 2000-2001. He is also
a member of the Licensing Executives Society and the Association of University
Technology Managers. Tom was named by Boston Magazine as a “Massachusetts
Super Lawyer” in intellectual property for 2004 - 2006.
[back to top]
Ron Epstein
Ron Epstein has over 17 years of experience in developing, optimizing and
monetizing IP asset portfolios. As General Counsel at Brocade, Ron recognized
that while there were plenty of very fine law firms, consultants and the like
that could solve parts of the overall IP problem, no one was focused on the
big picture of putting these pieces together. In response, at the end
of 2003 Ron has formed, and is now the CEO of, IPotential, an "IP
Strategic Brokerage," dedicated to assisting clients in developing and
monetizing patents.
Prior to founding IPotential, Ron was vice president and general counsel
at Brocade Communications Systems, Inc, and served as Director of Licensing
at Intel Corporation, where he was responsible for the company's IP licensing strategy, including
defense against assertions, and the creation of Intel's value licensing
program.
Ron built his legal career at Wilson, Sonsini, Goodrich and Rosati as a
member of the Technology Licensing Group, where he specialized in helping
clients minimize liability under the patent portfolios of leading companies
such as IBM, Lucent, and Intel; and negotiating patent cross-license agreements
in conjunction with complex patent litigation settlements.
[back to top]
Walter Flamenbaum
Walter Flamenbaum, M.D., is a Founding Partner of The Paul Royalty Fund,
and has led the development and refinement of its investment strategy, processes
and techniques, as well as actively participating in the majority of the Fund’s
investments, including roles in sourcing, negotiating and other activities.
Dr. Flamenbaum’s broad based medical knowledge and experience provides the
Fund with a unique resource for healthcare investing. He was primarily responsible
for the development of the diverse team of healthcare and financial investment
professionals, allowing for the Fund’s development and successes to date.
Dr. Flamenbaum has 35 years of healthcare experience, including the development
and evaluation of pharmaceutical and biotechnology based-drugs, medical devices
and diagnostics. During the 10 years prior to joining Paul Capital Partners
in 1999 as a founding member of the Paul Royalty Team, he has extensive experience
in the licensing of healthcare product-related intellectual properties and
the assessment of healthcare investing opportunities. He also founded a contract
research organization, started a biomedical company, and had senior management
responsibilities in a biotechnology company. He is board certified in internal
medicine, nephrology and clinical pharmacology and was a professor of medicine
at the Mt. Sinai School of Medicine and Tufts University School of Medicine.
Dr. Flamenbaum served in the US Army at the Walter Reed Army Institute of
Research and the Walter Reed Army Medical Center. He earned his M.D. from
Columbia University’s College of Physicians & Surgeons and his B.A. from Washington
& Jefferson College.
[back to top]
Joseph D. Fondacaro, PhD
Dr. Fondacaro received his Ph.D. in Physiology in 1972 from the University
of Cincinnati College of Medicine. Following a 3-year postdoctoral fellowship
at Albany Medical Center in New York, he returned to the Cincinnati College
of Medicine as Associate Professor of Physiology for 8 years. Dr. Fondacaro
then joined the pharmaceutical
industry for 15 years, initially with what is now Glaxo SmithKline and later
with Marion Merrill Dow as a scientist in discovery research and as Director
of Sponsored Research where he became involved in licensing and sponsored research
activities. In 1996, Dr. Fondacaro joined Cincinnati Children's Hospital
Research Foundation to establish an
office of technology transfer. Dr. Fondacaro is active in a local biomedical
incubator program in Cincinnati and serves on the Board of Directors for BioStart
and the Cincinnati Foundation for Biomedical Research and Education. He
holds a faculty position at the University of Cincinnati College of Medicine
and lectures on Ethics in Intellectual Property Management. He consults
on technology transfer issues for NSABP, Inc., Michigan Public Health Institute
and several academic centers. Dr. Fondacaro teaches a 2-day course on Creating
an Office of Technology Transfer. He serves on several AUTM committees
including Central Regional Planning and is currently AUTM Vice President for
Professional Development. He is past chair for the Industry-University
Transaction Committee of LES. He has published relevant articles on university
licensing and technology transfer. Dr. Fondacaro is currently Director
of Intellectual Property and Venture Development for Cincinnati Children's
Research Foundation.
[back to top]
Beth Fordham-Meier
Beth Fordham-Meier has nearly 20 years experience in business development
and licensing, intellectual property asset management, and technology transfer. She
is Senior Director of Business Development and Chair of the Intellectual Property
Committee at Targacept, Inc. (Nasdaq: TRGT), a clinical-stage biopharmaceutical
company that discovers and develops NNR Therapeutics™ for central nervous
system diseases and disorders. Since joining Targacept in 2003, Ms.
Fordham-Meier has held positions of increasing responsibility and served as
a key member of the business development and transactional team that secured
Targacept's nearly $300 million transforming cognition/schizophrenia deal
with AstraZeneca. Before joining Targacept, Ms. Fordham-Meier was Vice
President of Business Development for Pilot Therapeutics and served as Director
of Technology Transfer and Industry Relations at Wake Forest. Ms. Fordham-Meier
began her career in licensing and IP management at The University of Iowa
and the law firm of Dann, Dorfman, Herrell and Skillman in Philadelphia.
[back to top]
Douglass Given, MD, PhD, MBA
Douglass Given, MD, PhD, MBA, is a Partner at Bay City Capital and has been with
the firm since October 2000. He was formerly Chief Executive Officer and a
director of NeoRx, and Corporate Sr. Vice President and Chief Technical Officer
of Mallinckrodt. Prior to Mallinckrodt, Dr. Given served as Chief Executive
Officer and a director of Progenitor and Mercator Genetics. He held positions
as Vice President at Schering Plough Research Institute, Vice President at
Monsanto/G.D. Searle Research Laboratories, and Medical Advisor at Lilly Research
Laboratories. Dr. Given is the Chairman of VIA Pharmaceuticals and a member
of the board of directors of SemBioSys Genetics and Aksys, Ltd. He is also
a member of the Visiting Committee to the Division of Biological Sciences and
the Pritzker School of Medicine at the University of Chicago and the Johns
Hopkins Bloomberg School of Public Health Advisory Board.
[back to top]
Jorge A. Goldstein, Ph.D., Esq.
Jorge Goldstein is presently the Managing Director of Sterne Kessler Goldstein
and Fox, PLLC, a 250 person IP law firm in Washington DC. He is the Founder
of its Biotech/Chem Practice and head of its Patent Office Litigation Practice.
Dr. Goldstein has almost 30 years of experience in preparing and prosecuting
patent applications; contesting interferences, oppositions and arbitrations;
litigating in District and Appellate courts, both as counsel and expert witness;
and counseling clients on intellectual property portfolio strategies, trade
secrets, due diligence, licensing and research agreements, evaluation of patent
portfolios, and the IP aspects of mergers and acquisitions. He has lectured
extensively on IP topics. Noteworthy among several appellate cases, in 1988
Goldstein was lead counsel in In re Wands et al. 8 USPQ2d 1400
(Fed. Cir.), a pivotal decision on biotechnology enablement and deposit requirements.
The Legal Times of Washington, after a poll of clients and peers, chose him
twice as a "Leading Lawyer" in Washington D.C.: In 2003 as
one of the top IP Attorneys and again in 2006 as one of the top Life Sciences
Attorneys.
Education
- Juris Doctor, The George Washington University, with high honors, 1982
- Doctor of Philosophy, Chemistry, Harvard University, 1976
- Bachelor of Science, Rensselaer Polytechnic Institute, 1971
Recent Publications
Jorge A. Goldstein, "IP Boutiques: Surviving and Thriving," IP
LAW360, October 2006
Jorge A. Goldstein and Tim Shea, "Scientific
Collaborations and Inventorship Disputes," 12 IP Litigator 18,
November December 2006.
Ted Ebersole, Marvin Guthrie and Jorge Goldstein, "Patent
Pools and Standard Setting in Diagnostic Genetics," Nature
Biotechnology, 23 (8), August 2005
Goldstein, J.A. and Golod,
E., "Human Gene Patents," Acad
Med 77: 1315-1328 (2002).
Goldstein, J.A., "Patenting
the Tools of Drug Discovery," Drug
Discovery World, 9-18, Summer 2001
[back to top]
Larry Goldstein
Larry Goldstein is Vice President of Intellectual Property, Patent Pools & Licensing,
at Sedna Patent Services, which is a consortium of companies formed to help manage
patent rights in the cable business. Larry’s responsibilities include
managing a portfolio of U.S. and international patents, representing the company
on patent pools, identifying and evaluating patent portfolios for possible investment,
and out-licensing of various patents.
Prior to working at Sedna, Larry helped launch the 3G UMTS patent pool. He
managed intellectual property for various telecommunication companies including
Comverse Network Systems (a supplier of software products to large telephone
companies), and he has worked in business development and legal positions
for Motorola and for telecom companies in the U.S. and abroad. Prior
to his corporate work, he was a commercial litigator in the areas of contracts
and antitrust.
Larry is a registered U.S. patent attorney, and the chairman of the Standards
Committee of the High Tech Sector within LES. He is a co-author of the
book Technology Patent Licensing: An International Reference on 21st Century
Patent Licensing, Patent Pools and Patent Platforms (Aspatore Books,
Boston, 2004).
[back to top]
Kara Gorski
Dr. Gorski is an economist who specializes in the application of microeconomic
theory to intellectual property valuation and regulation. She has conducted
economic analyses of commercial litigation damages related to intellectual
property, breach of contract and antitrust. She has experience in estimating
lost profits, reasonable royalties, price erosion and unjust enrichment damages.
Dr. Gorski's experience spans various industries, including medical
devices, semiconductors, telecommunications and consumer products.
[back to top]
Robert R. Gruetzmacher, Ph.D.
Dr. Gruetzmacher is the Director of Technology
Commercialization in DuPont's Center for Collaborative Research and Education.
During his career with DuPont, his responsibilities have included research,
development, manufacturing, and marketing in the photopolymer imaging products
and medical diagnostic businesses. He managed DuPont's infectious disease
diagnostics research group in Boston, co-managed a food quality assurance
business venture, and helped lead development of DuPont's technology transfer
group and intellectual assets business.
In his current role in the Center for Collaborative Research and Education
he manages the unrestricted grants program, helps lead DuPont's efforts
to find appropriate university partners for sponsored and collaborative research,
negotiates agreements and seeks new business opportunities with the academic
setting, and advises company-wide on licensing-related matters. Most
recently, he has been asked to take a lead in facilitating corporate-wide
implementation of an "open innovation " R&D model.
Dr. Gruetzmacher holds a Ph.D. from Case Western Reserve University, and
was the recipient of a National Institutes of Health Postdoctoral Fellowship. He
has served as a trustee of the Licensing Executives Society and participates
in several international forums dealing with topics such as university/company
transactions, knowledge management, and the management and valuation of intellectual
assets. He has authored publications and is invited frequently to gives
talks on these topics. He is a member of the Licensing Executives Society,
the American Chemical Society, the Association of University Technology Managers,
and the American Association for the Advancement of Science.
[back to top]
Bradley J. Hulbert
Brad Hulbert is a founding partner in McDonnell Boehnen Hulbert & Berghoff,
an 75-lawyer IP firm in Chicago. Mr. Hulbert is also an Adjunct Professor of
Law and Director, Academic and Professional Program Development, at the Chicago-Kent
Law School. He has had substantial experience negotiating and drafting patent
licenses over the past 25 years.
[back to top]
Naoki Iguchi
Practice
Naoki Iguchi advises clients in a wide range of dispute resolution matters, with
a particular emphasis on intellectual property cases, international litigation
and commercial arbitration. Naoki Iguchi belongs to practice groups of Intellectual
Property Law; Litigation; and Chinese Law.
Lectures & Presentations
- "Art & Law," lectured at the Intensive Course "Public
Policy for Culture and City" of Kyoto University Graduate School of Economics
(2006)
- "Employee's Invention;" Does it apply
to Japanese Universities?" presented at LES 2007 Winter Meeting,
San Francisco (2007)
Publications
- "U.S. Distributor Protection Laws (1)(2)(3)(4)(5)(6)," JCA
Journal (October 2006 through March 2007)
- "Copyright 2006," Law Business Research (2006)
(co-author)
- "Dispute Resolution 2003, 2005 & 2006," Law Business
Research (2003, 2005 & 2006) (co-author)
Education & Training
The University of Tokyo (LL.B., 1992; LL.M., 1999); The Legal Training
and Research Institute of the Supreme Court of Japan, 1999-2000; language
training, Beijing Language University (2002); graduate study, Stanford
Law School (LL.M., 2006). Associated with Saint Island International
Law Offices, Taiwan, June 2005-July 2005; Finnegan, Henderson, Farabow,
Garret & Dunner LLP, Washington,
D.C. and Reston (Virginia), September 2006 - present.
Professional Admissions
-
Japan (2000), Dai-ni Tokyo Bar Association
Business Associations
- Associate Member, Computer Law Research Society
- Deputy Secretary General of Japan Aribitrators Assocation: responsible
for international and public affairs
- International Bar Association
- License Executive Society (U.S.-Canada)
- American Intellectual Property Law Association
Languages
- Japanese (first language)
- English
- Chinese (Mandarin)
[back to top]
Steve Jakubowski
Steve Jakubowski, a lawyer with the Coleman Law Firm in Chicago, has worked
in complex chapter 11 bankruptcies for 22 years: twenty as a lawyer;
two as Court-appointed CEO/COO. He also founded the Bankruptcy Litigation
Blog (www.bankruptcylitigationblog.com), which
now averages about 11,000 page views monthly from about 3,500 unique sites.
[back to top]
Bradley Johnsen
Brad Johnsen is Senior Corporate Counsel
and Director of Commercial Transactions for Marvell Semiconductor, Inc., a
fabless semiconductor company in Santa Clara, CA. Prior to joining Marvell, he served as Senior Corporate Counsel at
Netscreen Technologies, Inc. and as an associate at Pillsbury Winthrop in the "Technology
Transactions & Licensing" group. At Marvell, Mr. Johnsen oversees
the review and negotiation of inbound and outbound license and development
agreements for Marvell's software and hardware products.
[back to top]
George W. Jonas
George W. Jonas is a registered patent attorney with nearly a decade of experience
in all aspects of intellectual property, including patent filing strategy,
litigation, prosecution and licensing. George is intellectual property
counsel at 3M Company, a world leader in innovation. George currently
represents 3M's Display and Graphics Business and previously represented their
Consumer Business. Prior to working with 3M, he worked at a patent boutique
law firm. George is licensed to practice by the U.S. Patent & Trademark
Office and the Minnesota and Wisconsin State Bars.
[back to top]
Stuart Kaler
Stuart Kaler is General Counsel for Clairvoyante, Inc -- a venture-backed
Silicon Valley start-up that licenses unique subpixel rendering technology
to the display industry. As an intellectual property attorney
for the last 15 years, Stuart has counseled a diverse set of clients, from
large multinational concerns to venture-backed start-ups. Mr. Kaler has held
senior in-house IP counsel positions at Siemens and Xerox PARC, as well as
with law firms Morrison Foerster and Flehr, Hohbach, Test, Albritton Herbert.
[back
to top]
David J. Kappos
Mr. Kappos is Vice President and Assistant General Counsel, Intellectual Property
Law, for IBM Corporation. Based in Armonk, New York, Mr. Kappos directs
IBM's Intellectual Property Law function, providing legal counsel over
all facets of protecting the licensing IBM's intellectual property assets
and leading IBM's engagement of intellectual property law policy issues. In
particular, Mr. Kappos is responsible for the management of IBM's patent
and trademark portfolios; protecting and licensing intellectual property
(patents, copyrights, trademarks, know how and technology) worldwide; directing
intellectual property law operations relating to the research, marketing,
services, consulting, systems, storage products, semiconductor and technology development,
printers and personal systems, software and other groups, divisions, and entities
within IBM. In addition, Mr. Kappos has responsibility for IP policy
and coordination with IBM's litigation and corporate development groups
in matters relating to intellectual property.
Mr. Kappos serves on the Board of Directors of the American Intellectual
Property Law Association, the Intellectual Property Owners Association, and
the International Intellectual Property Society. He has held various
previous leadership positions in intellectual property law associations in
Asia and the U.S. He has spoken widely in Asia, Europe, and the U.S.
on intellectual property topics.
Mr. Kappos received his Bachelor of Science Degree in Electrical and Computer
Engineering from the University of California Davis in 1983, and his law degree
from the University of California Berkeley in 1990. He joined
IBM in 1983 as a Development Engineer and has served as an Intellectual Property
Law attorney in IBM's Storage Division and Litigation group, as IP Law
Counsel in IBM Software Group, as Assistant General Counsel in IBM Asia/Pacific,
IBM Corporate Counsel and as Assistant General Counsel prior to his current
position.
[back to top]
D. Brian Kacedon
Brian Kacedon is a member of the firm's Mechanical Practice Group, where
his practice includes patent licensing, patent litigation, patent prosecution,
and patent opinion work.
A substantial portion of his practice includes patent
licensing and related litigation for various technologies used in consumer
electronics products. Mr. Kacedon's role in these matters has included
assisting clients in conducting market assessments for their patents, conducting
licensing negotiations, drafting licensing agreements, and participating fully
in related litigations. Mr. Kacedon also has extensive experience in drafting
patent, know-how, and software license agreements in many other industries.
Mr. Kacedon's practice also includes preparing opinions on patentability,
infringement, and validity, and handling all phases of preparing and prosecuting
patent applications before the U.S. Patent and Trademark Office.
In addition
to practicing law, Mr. Kacedon has lectured widely on licensing. He is currently
an Adjunct Professor teaching licensing at the George Mason University Law
School. For several years he has presented courses for drafting patent and
know-how licenses for the Patent Resources Group as well as other organizations.
He is also active in professional organizations including the Licensing Executives
Society (U.S.A. and Canada), where he currently serves as Secretary of the
High Technology Sector.
Admitted:
2000, Maryland; 2001, District of Columbia;
registered to practice before the U.S. Patent and Trademark Office.
Education:
New York University School of Law (J.D., 2000); Duke University (B.S.M.E.,
cum laude, with distinction, 1997).
Association Involvement:
Maryland Bar
Association; American Intellectual Property Law Association; Licensing Executives
Society.
Representative Publications:
Coauthor, "Patent Trolls: A Stereotype
Causes a Blacklash Against Patents and Licensing," Les
Nouvelles, December
2006.
[back to top]
Kathleen M. Kedrowski, CPA
Kathi is a Managing Director in Navigant's
Litigation and Consulting Service and is a national expert in the intellectual
property practice. With over 20 years experience, Kathi
performs a variety of economic, business and financial analyses
on behalf of clients in intellectual property, licensing and other
disputes as well as advises clients on the strategic use of
intellectual assets. Kathi has testified as a damages and licensing
expert in both Federal and State court as well as before
arbitration tribunals. Kathi is a frequent speaker and writer on
topics involving intellectual property. Kathi was previously a
Partner with Ernst & Young, Andersen and a Director at LECG.
[back to top]
Stefan Koehler
Stefan has been working as a Licensing Professional
for Epicentre Biotechnologies, a
developer and manufacturer of molecular biology research reagents, for four
years. He negotiates Agreements on a daily basis. Previously, Stefan taught
business classes at the University of Munich Entrepreneurship Center and the
University of Wisconsin Business School and worked for KPMG as a consultant
in Financial Advisory Services . He holds an M.S. in Molecular Biology from
the University of Munich, Germany, and an M.B.A. from the University of
Wisconsin, Madison.
[back to top]
Katharine
Ku
Katharine Ku is Director of the Office of Technology Licensing (OTL)
at Stanford University. OTL
is responsible for the licensing of various state-of-the-art university
technologies and industry sponsored research agreements and collaborations.
In
FY2006, Stanford received $61.3M in gross royalty revenue from 463 technologies,
with royalties ranging from $12 to $29.0M.
From
1994-98, in addition to her OTL responsibilities, Ku was responsible for
Stanford's Sponsored Projects Office, which handled $500M in research
contracts and grants at the time. Ku was Vice President, Business Development
at Protein Design Labs, Inc. in Mountain View, California from 1990-1991. Prior
to PDL, Ku spent 12 years at Stanford in various positions, was a researcher
at Monsanto and Sigma Chemical, administered a dialysis clinical trial at
University of California, and taught chemistry and basic engineering courses.
Ku
has been active in the Licensing Executive Society (LES), serving as Vice
President, Western Region and Trustee of LES and various committee chairs. She
also has served as President of the Association of University Technology
Managers (AUTM) from 1988-90. She received the AUTM 2001 Bayh-Dole Award
for her efforts in university licensing.
Ku
has a B.S. Chemical Engineering (Cornell University), an M.S. in Chem. Eng.
(Washington University in St. Louis) and is a registered patent agent.
[back to top]
Mike Lasinski
Mike Lasinski is a Managing Director at Ocean Tomo in Chicago, Illinois, and
is in charge of the company’s valuation practice area. Mike serves clients
in the area of strategy, valuation and tax structure analysis. In the valuation
area, Mike has valued intellectual property and businesses in the context of
licensing, sale, purchase (including purchase price allocation), corporate
spin-outs, joint ventures, litigation (reasonable royalty and economic damage
analyses) and tax-related transactions. Mike has completed more than 200 valuations
during his professional career. He has spoken on the topics of IP valuation,
IP licensing and IP tax strategies throughout the U.S. as well as internationally.
In the strategy area, Mike has helped his clients establish intellectual
property management subsidiaries, licensing departments and intellectual asset
management groups throughout the world. He has also performed inventories
of company IP (including patents, trademarks, software, trade secrets and
other IP). In fulfilling such responsibilities, Mike has developed strategies
for clients surrounding licensing, sale, donation and abandonment of IP. For
strategies related to licensing or sale of intellectual property or businesses,
Mike has been a key member of the negotiation team.
Mike is currently the Treasurer and a former co-chair of the Valuation and
Taxation Committee of the Licensing Executives Society (LES). He is the current
Vice Chair of the Valuation and Taxation Committee of the Intellectual Property
Owners Organization. Mike is also a Certified Public Accountant in the State
of Illinois. Prior Ocean Tomo, Mike worked for InteCap, a subsidiary of Charles
River Associates, Coopers & Lybrand (now PriceWaterhouseCoopers) and Ford
Motor Company.
[back to top]
Ron Laurie
Ron Laurie is a co-founder and Managing Director of Inflexion Point Strategy,
LLC, an intellectual property investment bank formed in early 2004. Ron
has worked in Silicon Valley for over 40 years, first as a software engineer
and then as an intellectual property lawyer advising computer, communications,
semiconductor, media and financial services companies on IP strategy, a subject
he has taught at Stanford and Boalt (UC-Berkeley) law schools. Ron was
a founding partner of the Silicon Valley offices of Skadden Arps and Weil,
Gotshal, & Manges. As a lawyer, his primary focus was on the strategic
use of IP assets in complex business transactions such as mergers, acquisitions,
technology divestitures, joint ventures and strategic alliances, and Ron led
IP teams in some of the largest technology deals in history, worth over $50
billion.
Ron is a registered patent attorney and a substantial part of his earlier
legal practice involved strategic planning, commercial exploitation and litigation
of patents on cutting-edge software-based technologies such as artificial
intelligence, encryption and Internet business methods including the much
publicized Priceline patent. Ron has been listed in virtually every
peer review survey of leading IP lawyers including: Top 25 California IP Lawyers
(Daily Journal), Best Lawyers in America (Woodward-White), America's Leading
Business Lawyers (Chambers), Global Counsel 3000 (Practical Law Co.),
and International Who's Who of Business Lawyers (Law Business Research). He
has been an advisor to the U.S. Patent & Trademark Office, the U.S. Copyright
Office, the Office of Technology Assessment of the U.S. Congress, the National
Research Council, the National Academy of Science and the World Intellectual
Property Organization, a United Nations agency based in Geneva. He
is on the Executive Council of the Berkeley Center for Law & Technology
and is a permanent faculty member of the World Law Institute.
Ron is on the editorial boards of The Journal of Internet Law and The Computer
Lawyer magazines and co-edited a two-volume treatise titled International Intellectual
Property. He has been a Director of the Computer Law Association, and
has served on the Executive Committees of the International Intellectual Property
Association and the Intellectual Property Section of the State Bar of California. He
has lectured on intellectual property law topics at conferences of lawyers,
judges, engineers, company executives and government officials in the United
States, Japan, Europe, Australia and South America.
[back to top]
Dooyong Lee
Dooyong Lee is the Executive Vice President of Business Development at Acacia
Technologies Group in Newport Beach, California. Acacia is a publicly traded
company (NASDAQ: ACTG) in the business of acquiring, licensing and enforcing
patents. His organization is responsible for acquiring new patents and
partnering with patent holders. He was previously Chief Operating Officer
of Global Patent Holdings DBA TechSearch, which was acquired by Acacia in 2005.
Prior to Global, he was President of LPS Group, under Information Holdings
Inc. (now part of The Thomson Corporation, NYSE:TOC). Prior to LPS Group, he
co-founded FRI, an IP consulting firm under the sponsorship of Fish & Richardson,
PC and previously was a licensing executive at AT&T Bell Laboratories/Lucent
Technologies. He holds six U.S. patents and is the inventor of the popular
telemarketing feature that plays expected waiting time announcements to incoming
callers.
back to top]
David Lubitz
David Lubitz works at Microsoft Corporation and is a Senior Patent Attorney
in Microsoft's Intellectual Property and Licensing Department. David
handles third party patent claims made against Microsoft and he also handles
Microsoft's acquisitions of third party patents. David also works on
Patent Cross License Negotiations with companies located in Asia and the U.S.
Prior to joining Microsoft, David was the Managing Partner of Hogan & Hartson's
Tokyo Office from 2000 - 2005.
[back to top]
Eric C. Lund, Ph.D., MBA
Eric C. Lund has been a technology transfer and licensing professional since
1995, and since 2001 has been a Commercialization Manager at Battelle and
the Pacific Northwest National Laboratory. Before that, Dr. Lund was
an Analyst for the Washington Research Foundation at the University of Washington,
an Assistant Vice Chancellor of Research for the University of Illinois at
Urbana-Champaign, and the Assistant Director of Technology Transfer and Intellectual
Property Services at the University of California, San Diego.
Prior to entering into technology transfer and licensing, Dr. Lund worked
as a research chemist for several firms, and also taught chemistry as an adjunct
professor at the University of Washington, Montana State University, and Grossmont
College.
Dr. Lund received his B.S. in chemistry from Washington State University,
his Ph.D. in organic chemistry from the University of California, Davis, and
an MBA in finance and economics from the University of Washington.
[back to top]
Steven T. McMaster
Steven T. McMaster has been a Technology Licensing Manager
at the Mayo Clinic since 1999. He previously worked as Technology Licensing
Associate, Director of the Purchasing Department and in-house legal counsel
at Utah State University. He currently manages a diverse collection
of around 135 medical technologies including a portfolio of innovative 3D
medical imaging software, a portfolio of CT colonography patents and software,
several medical devices and several early stage biotechnology discoveries.
A graduate of the University of Utah, he received a B.A. degree in Business
Management (Spanish minor) and a J. D. degree.
[back to top]
Brian McTigue
Brian is Director of Business Development at Partners HealthCare, and currently
oversees the intellectual property marketing function within the business development
group. Prior to joining Partners, Brian spent almost 20 years in the pharmaceutical
industry in sales and sales management across a diverse set of products and
therapeutic areas, primarily in immunology related fields. Brian was part
of the original sales team at Centocor, and most recently was part of the team
that brought Prograf™ immunosuppressant to a dominant share in
the transplant market at Fujisawa (Astellas).
Brian holds a Bachelor of Business Administration from the University of New
Brunswick
[back to top]
David Meisels
David Meisels is the General Counsel of D&M Holdings US Inc. D&M
owns the Denon, Marantz, Boston Acoustics, Rio and ReplayTV consumer electronics
brands, among others.
Mr. Meisels supports all functions of the Company, including IP, licensing, e-commerce
and litigation. Notable matters he has been involved with include serial
copying legislation, and the ReplayTV v. Paramount litigation. Prior to
joining D&M, David was Associate General Counsel to SONICblue Incorporated
and Corporate Counsel at Concentrex Inc. He was in private practice at
Ater Wynne LLP in Portland, Oregon and at Davis Wright Tremaine in San Francisco.
[back to top]
Michel Mellinger
Mr. Michel Mellinger works at the National Research Council of Canada's
Institute for Information Technology. Prior to joining NRC-IIT, he was responsible
for the management of R&D and innovation in several Canadian organizations,
in the geomatics, spatial technology and environmental sectors. Before his
career in innovation management, M. Mellinger had a successful career in applied
research, in the areas of geology, geochemistry, and multivariate statistical
data analysis.
M. Mellinger obtained a M.Sc. in Strasbourg (France), and a M.Sc.A. in Montréal
(Québec). He is also a graduate of the Banff School of Management.
[back to top]
Nader Mousavi
Nader Mousavi is a junior partner in the Corporate Department of WilmerHale
in Palo Alto.
Mr. Mousavi concentrates his practice on technology and intellectual property
transactions. He has represented emerging and established clients in hundreds
of transactions involving the development, licensing, manufacturing, supply,
marketing, distribution and commercialization of products, technology and intellectual
property. He also has substantial experience advising clients in collaborations,
alliances, outsourcing, mergers, acquisitions, settlements, divestitures and
spinouts.
Representative clients of Mr. Mousavi include Cisco Systems, Palm, Broadcom,
Open Source Applications Foundation, Transitive, Digidesign, NanoNexus, ASML,
Novartis, Sanderling Ventures, Range Fuels, Attenuon, and AVEO Pharmaceuticals.
Prior to joining WilmerHale, Mr. Mousavi served as general counsel of TCS,
a telecommunications software company, where he was responsible for all legal
affairs from TCS' startup phase through its acquisition by Convergent Networks. Following
the acquisition, Mr. Mousavi served as senior counsel of Convergent Networks.
Mr. Mousavi received his J.D. from Stanford Law School and his B.A., summa
cum laude, from the University of California, Los Angeles.
[back to top]
Gwyn Firth Murray
Gwyn Firth Murray is founder and principal of the Matau Legal Group, which offers a
broad range of commercial, licensing, and other legal services to both start-up and
established companies in the high tech and biotech industries (see www.mataulegal.com).
She also is co-founder of Open Bar, Inc., a not-for-profit organization focused on legal
rights and responsibilities in the world of open source software (see www.open-bar.org).
Gwyn has spent over fifteen years working as inside and outside counsel to
computer hardware, computer software and pharmaceutical companies, including
Apple Computer, SGI, and Alza Corporation. Gwyn was the first lawyer to join
VA Linux Systems, Inc. (now “VA Software”) as internal counsel, and she served as Vice President, Legal
Services for VA during its first year as a public company. After leaving VA, she went on
to become Vice President and General Counsel of Kanisa Inc., a privately-held software
company based in Cupertino, California, before undertaking her own law practice.
Gwyn is a graduate of Stanford University Law School, and also holds an M.A.
in Latin American Studies from Stanford University. She obtained her B.A.
magna cum laude and with distinction in economics from Yale College. Gwyn
is fluent in Spanish and Portuguese.
[back to top]
Gary M. Nath
Gary M. Nath is the founder and Managing Partner of The Nath Law Group, an
intellectual property (IP) law firm with offices in the Washington, DC area
and San Diego, California. Mr. Nath is a patent attorney and legal advisor
to a wide array of clients including major U.S., European and Asian multinational
corporations; universities and other research institutions; small businesses
and start-up companies; and sole inventors and entrepreneurs. Mr. Nath
draws from his experience as Patent Counsel for three Fortune 500 companies,
his entrepreneurial savvy gained as a founding member of more than ten start-up
companies, and as founder of The Nath Law Group. He has advanced scientific
training in chemistry, biology, and physics that enables him to guide clients
in all aspects of IP law, including patent and trademark prosecution and litigation,
with a particular emphasis on the strategic development and management of
a client's patent and trademark portfolio.
As a corporate attorney, Mr. Nath was an integral part of the Patent and
Trademark law departments of several multinational companies: FMC Corporation,
NL Industries, and Warner-Lambert Company where he served as patent attorney,
Group Patent and Trademark Counsel and General Patent Counsel, respectively
for these Fortune 500 companies. Mr. Nath began his patent career as
an Examiner at the U.S. Patent and Trademark Office in 1969, following a brief
career teaching biology, chemistry and physics.
Mr. Nath is a Member of the Board of Trustees of the Licensing Executives
Society (USA and Canada) and is an International Delegate to LESI. Mr.
Nath is also a member of AIPLA, AIPPI, AUTM, INTA, FICPI, TEC, and other professional
organizations. He has been a speaker before numerous domestic and international,
professional and lay groups on intellectual property law procurement, enforcement,
licensing, financing and technology transfer. He is a member of the
Science Advisory Board at Rider University.
[back to top]
Jack Nightingale
Jack Nightingale has 22 years of business development, product development,
strategic planning, executive management, and management consulting experience. He
led global business development activities for a $3 billion division of Honeywell
for 5 years. As President of a biotechnology company, he was responsible
for licensing research technologies and intellectual property to major pharmaceutical
and biotechnology companies. Most recently, he has served as a management
consultant on business development to leading global pharmaceutical, biotechnology,
medical diagnostics, and consumer healthcare companies. Mr. Nightingale
received a Bachelor of Arts degree from Harvard University and an M.P.A. in
Economics and Public Policy from Princeton University.
[back to top]
Patrick O'Reilley
Patrick O'Reilley leads the firm's technology
transactions practice and is a recognized expert in the field. He focuses
almost exclusively on transactions involving intellectual property and technology
transfer.
Mr. O'Reilley counsels large and small clients on many types of transactions
involving intellectual property, ranging from simple license agreements to complex
research and marketing collaborations. He assists clients in all phases of such
transactions, including formulating strategies for exploiting intellectual property
to achieve desired business goals and negotiating and drafting intellectual property-related
agreements, such as employment, consulting, joint R&D, license, marketing
and distribution, supply, and collaboration agreement. He guides clients through
disputes arising from technology transfer contracts and helps clients formulate,
negotiate, and prepare agreements settling disputes. He represents clients as
licensors and as licensees in all industries that employ technology transactions,
and he has particular experience in transactions in the pharmaceutical, biotechnology,
telecommunications, and electronic industries.
In addition to his transactional work, Mr. O'Reilley assists clients in
obtaining and enforcing their intellectual property assets. In his career, he
has filed and obtained hundreds of domestic and foreign patents and trademarks.
He has also played significant roles in numerous trademark infringement, patent
infringement, and trade secret misappropriation litigations in federal and state
courts and in the International Trade Commission. Mr. O'Reilley's
litigation experience includes several trials and post-trial appeals, representing
both owners and alleged infringers in many diverse technical fields, and many
more litigations where he assisted in settlement.
Mr. O'Reilley has lectured and published on technology licensing and related
antitrust issues. He is currently an Adjunct Professor teaching licensing at
the George Mason University Law School. For over ten years he has presented courses
on drafting patent and know-how licenses for the Patent Resources Group. He has
also written many articles on licensing and related competition law matters.
He is coauthor of a widely used text on drafting patent and know-how license
agreements. He was president of the Licensing Executives Society (USA & Canada)
for the 2004-05 year.
Mr. O'Reilley has served in numerous management positions in the firm,
including vice-chairman of the Management Committee.
Admitted:
1975, District of Columbia; 1975, U.S. Court of Customs and Patent Appeals;
1982, U.S. Court of Appeals for the Federal Circuit; registered to practice
before the U.S. Patent and Trademark Office.
Education:
The George Washington University National Law Center (J.D., 1975); United
States Naval Academy (B.S., Engineering, 1966).
Association Involvement:
The District of Columbia Bar; Bar Association of the District of Columbia;
American Bar Association; American Intellectual Property Law Association;
Licensing Executives Society.
Representative Publications:
“Licensing in a Flat World,” les Nouvelles, June 2006,
and LES Viewpoints, August 2005; Coauthor, Drafting Patent License
Agreements, 5th ed., BNA, 2004.
[back to top]
Brian Oliver
Brian Oliver is Director, Business Development - Intellectual Property at the
Chicago Mercantile Exchange (CME), in Chicago, Illinois. The CME is the
world's largest and most diverse financial exchange, offering futures and options
on futures primarily in four product areas: interest rates, stock indexes,
foreign exchange and commodities. Brian is working with others at the CME in
developing and maintaining CME's overall intellectual property (IP) program,
including identifying areas of need and opportunity for CME to develop or acquire
IP assets, developing and strengthening processes for identifying CME's IP
assets, implementing licensing strategies and serving as the business owner
for critical licensing relationships, and playing an active role in evaluating
and pursuing acquisition opportunities that may benefit CME in terms of IP. Prior
to CME, Brian was a Vice President for CRA International, an economics, finance
and business consulting firm. At CRA, Brian was responsible for representing
clients in all aspects of IP-driven transactions and improving IP business
operations. While at CRA, Brian worked on several projects for CME, including
the successful renegotiation of its Standard & Poor’s license agreement. Brian
has also held past positions in investment banking and corporate finance.
[back to top]
Nancy
Patterson
Nancy Patterson is a Venture Analyst and the Vice
President, for the Alfred E. Mann Foundation for Biomedical Engineering, a
philanthropic Foundation endowed with $2 billion targeted to created a new
generation of university-based biomedical institutes. The twelve institutes,
to be entitled Alfred E. Mann Institutes will focus on the translation and
commercialization of compelling biomedical technology supporting the university
researchers who maintain the intellectual property.
Ms. Patterson has over 18 years experience in senior business development and
marketing roles with emerging technology medical device companies, the last
three of which were acquired by multinational medical companies for $205M, $387M
and $508M. She has been a Board Member of the Global Medical Marketing
Association, as well as a frequent contributor to Medtech Insight, Cardiovascular
Device Update and the BBI Newsletter. In 2004 and 2005 Ms. Patterson taught
a series of classes at the University of California at Irvine on Securing Funding
for Your Compelling Medical Device Technology. In 2006 she was a guest
lecturer at UCLA in the Business of Science class series. Ms. Patterson
has an MBA from University of Southern California with a combined Finance and
Marketing focus. She also has an undergraduate degree in chemistry
and a graduate focus in Immunology.Ms. Patterson's company,
Strategy Inc. provides business development consulting and technology assessment
to the MedFocus Fund, a medical device incubator/ accelerator venture capital
fund and several emerging technology medical device companies.
[back to top]
John C. Paul
John Paul is a partner in Finnegan Henderson's Washington, D.C. office and
serves as the firm's IP Management Section leader. He has over twenty years
of experience in IP licensing, litigation, and prosecution, and he currently
focuses on strategic planning, due diligence investigations, and licensing
of IP portfolios.
He has set up and directed licensing and enforcement programs for leading
technology companies that generated significant royalty revenue. He has helped
clients understand the legal and commercial significance of IP portfolios
and develop more robust portfolios aligned with their business objectives
in fields including multimedia electronics, medical devices, and consumer
products. And he has conducted due diligence investigations in all fields
to identify, evaluate, and protect proprietary technology positions during
startup, financing, product development, licensing, cooperative ventures,
and acquisitions.
Mr. Paul has lectured widely on patent law, licensing, and IP management,
and for many years has coauthored a quarterly review of recent developments
in licensing law for the Licensing Executives Society journal Les Nouvelles.
He has taught patent law as a member of the adjunct faculty of the Catholic
University of America Law School. And he has held leadership roles in professional
organizations including the American Bar Association, the American Intellectual
Property Law Association, the American Society of Mechanical Engineers, and
the Licensing Executives Society.
Admitted:
1979, Ohio; 1981, District of Columbia, U.S. Court of Appeals for the District
of Columbia; 1982, U.S. District Court for the District of Columbia, U.S.
Court of Appeals for the Federal Circuit; 1983, U.S. Supreme Court; registered
to practice before the U.S. Patent and Trademark Office.
Education:
Case Western Reserve University School of Law (J.D., 1979); Brown University
(A.B., Mechanical Engineering, 1976).
Association Involvement:
Association of the District of Columbia (Amicus Brief Subcommittee of the
CAFC Committee, 1982-1984; Board of Directors, Young Lawyers Division, 1982-1986;
Executive Council, Young Lawyers Section, 1987-1990); Federal Circuit Bar
Association (Board of Directors, Young Lawyers Division, 1982-1986); American
Bar Association (Chairman, District of Columbia Young Lawyers Division Membership,
1983-1990; Vice-Chairman, Young Lawyers Division, Patent, Trademark and Copyright
Law Committee, 1989-1990); American Intellectual Property Law Association
(Chairman, India Subcommittee, Foreign and International Law Committee, 1994-1995);
Licensing Executives Society (Chairman, Washington Chapter, 1994-present);
American Society of Mechanical Engineers (Industry/Laboratory Technology Transfers
Committee; Chairman: Technology and Law Committee; Chairman: Technology and
Society Division); American Chamber of Commerce in Italy (Intellectual Property
Law Committee); Washington Area Lawyers for the Arts (Board of Directors,
1997-present).
Representative Publications:
Coauthor, “Patent Trolls: A Stereotype Causes a Blacklash Against Patents
and Licensing,” Les Nouvelles, December 2006; Coauthor, “Recent
Decisions in the United States,” Les Nouvelles, September 2006;
Coauthor, “Recent Decisions in the United States-A Recurring Feature,” Les
Nouvelles, March 2006; Coauthor, "Opportunities and Challenges
Arising from Nanotechnology Inventions," International Fiber Journal,
June 2004; "Recent Developments in the Law Relating to Licensing," Les
Nouvelles, 1991-present; "Licensing to South Korea," Les
Nouvelles, Sept. 1995; "Licensing to Korea: 1997," Les Novelles,
June 1998.
[back to top]
Karthika Perumal
Karthika Perumal joined the University of Texas Medical Branch in
2001 and in her current role as the Assistant Director of Technology
Development, she is responsible for managing technologies that originate
with UTMB faculty and staff. She has experience in technology assessment,
patent portfolio development and in negotiation of cash and
equity-based license transactions. She holds a bachelors degree in Industrial
Biotechnology from Anna University, Chennai, India and Ph.D. in Pharmacology
from the Baylor College of Medicine, Houston, Texas.
[back to top]
Denise K. Pierce
Denise Pierce has more than
26 years of experience encompassing leadership roles in product marketing,
new product planning, and medical economics/reimbursement planning in the
biopharmaceutical industry with such companies as Pfizer, Bristol-Myers Oncology,
and AMGEN. Subsequent to her biopharmaceutical
tenure, Denise was a Principal and Director at Covance Health Economics and
Outcome Services, a global reimbursement and outcomes consulting firm. Since
2000, Denise has continued reimbursement planning and implementation consulting
in her own Indiana-based corporation, D K Pierce & Associates, Inc.
Denise's reimbursement expertise lies with injectable and oral drugs
and biologicals in the oncology arena. Her company works directly with
national and local Medicare, Medicaid and managed care offices, as well as
with hematology/oncology medical specialty societies and employers to analyze
the evolving oncology environment and help establish positioning for novel
medical technologies. A significant mission of her company is to connect
all stakeholders in the healthcare environment to create access to quality
patient care.
Denise received her Bachelor of Science degree from Fairleigh Dickinson University
in New Jersey.
[back to top]
Joseph Potvin
Joseph Potvin is an IT economist with Enterprise Technology & Application
Strategies Sector, Chief Information Officer Branch, Treasury Board Secretariat,
Government of Canada. He manages the establishment of Intellectual Resources
Canada. IRCan is being created to provide structured co-authoring, version
management, issue management, and business services to enable the pooling
of financial, intellectual and technology resources amongst public sector,
commercial, academic and civil society participants, for the creation and
evolution of joint and collective copyright assets that are of interest to
the Government of Canada. It provides a business design and public sector
policy framework for collaborative evolution of know-how across organizational
and sectoral boundaries, thereby optimizing knowledge-sharing and organizational
learning for the benefit of Canadian taxpayers. Potvin also leads the ITERation
Project (IT for Expenditure Reporting Automation), the first open source project
initiated by Treasury Board Secretariat. On his own time, Potvin is
co-coordinator of GOSLING (Getting Open Source Logic INto Governments), a
voluntary, informal learning and knowledge-sharing community of practice,
involving civil servants and other citizens who actively assist the engagement
of free/libre open source methods and software solutions in government operations.
Mr. Potvin completed an Honors BA (economics) at McGill University in 1983,
and a Masters Degree (economics and technology) at Cambridge University, England
in 1986.
[back to top]
Linda M. Pullan, Ph.D.
Linda M. Pullan, Ph.D. is the founder of Pullan Consulting (lpullan@msn.com;
805-558-0361), offering biotech business development consulting. With
over 20 years of pharmaceutical and biotech experience, Pullan Consulting
can provide in-depth understanding and proven success in drug development,
and evaluation, valuation and negotiation for strategic alliances and licensing
deals. Pullan Consulting can help create business plans, partnering
presentations, market forecasts and financial calculations, partnering strategies,
and deal structures.
Linda was previously VP of Business Development at Kosan Biosciences, where
she was responsible for all business development activities, strategy, market
analysis, financial models, messaging, relationship management and negotiations. She
gained experience in natural products and anti-infectives, in addition to oncology.
Prior to joining Kosan, Linda was the Director of Licensing at Amgen where
she created and led licensing team of 10 (including legal and finance) for
Amgen's
biggest therapeutic areas, oncology and hematology, antibody and small molecule
drug candidates and technologies.
Linda began her pharmaceutical industry experience as a drug discovery researcher
in neuroscience at Monsanto/Searle (now part of Pfizer) and later at AstraZeneca. At
AstraZeneca, she switched to licensing, working on technologies and early drug
candidates for all therapeutic areas.
Her Ph.D. is in Biochemistry from the University of California at Riverside,
and her BS is in Chemistry from the University of Utah. She has authored
66 publications. Her deal sheet lists 8 major deals and more than 10 others.
[back to top]
John Reid
John Reid is Director of Global Alliance Management, Strategic Planning and
Business Development –Neuroscience at AstraZeneca Pharmaceuticals. In
this role, Dr. Reid combines training and experience in drug discovery research
and business development. He also acts as Neuroscience coordinator for
research collaborations in Japan. Previous positions with AstraZeneca
CNS Drug Discovery US include Director of Knowledge Management and Director
of the Molecular Sciences Department, responsible for exploratory research
in Neurology and Psychiatry. Before joining Astra in 1997, he was scientist
and group leader at the Glaxo Institute for Molecular Biology in Geneva, Switzerland,
where he directed research in signal transduction and developed new screening
systems. He started his career in biotechnology in 1981 at Genentech in San
Francisco. Dr. Reid received his Ph. D. from the University of California,
Berkeley and his B. Sc. from UC Davis. Dr. Reid's research career focused
on membrane proteins and signal transduction including the discovery and functional
characterization of novel G-proteins and potassium channels. He has served
as an expert reviewer for several scientific journals, advisor for the European
Commission, and occasional consultant and advisory board member for scientific
events.
[back to top]
Linda Robertson, Ph.D.
Dr. Robertson is an experienced senior regulatory professional with over fifteen
years in the pharmaceutical industry and extensive knowledge of international
biologic and small molecule drug development. Her regulatory expertise includes
a variety of therapeutic areas, e.g., oncology, rheumatology, virology and
neuropharmacology. She currently serves as Vice President of Regulatory Affairs
and Quality Assurance at Kanisa Pharmaceuticals, an oncology-based pharmaceutical
company located in San Diego, California. Prior to Kanisa, she was Director,
Drug Regulatory Affairs at Biogen IDEC, Inc. and its predecessor company, IDEC
Pharmaceuticals with responsibilities for several oncology products including
Rituxan. She has also served in various senior Global Regulatory Affairs
positions at Roche Pharmaceuticals in Nutley, New Jersey and Palo Alto, California.
Dr. Robertson received undergraduate training from Lewis and Clark College,
her Ph.D. in neurobiology from Northwestern University, and additional post-doctoral
training in molecular biology from the Roche Institute of Molecular Biology.
[back to top]
Oscar A. Rosenbloom
Oscar A. Rosenbloom specializes in licensing and technology
transactions and is a member of Axiom Legal in San Francisco. He
was Chairman of the Patent Committee, and Intellectual Property Counsel at
Amdahl Corporation (1985 – 1994), Senior Products Law Attorney at Apple
Computer (1994 – 2000) and Senior Intellectual Property Counsel at Synopsys
(2001). As early as 1990 he worked with open source at Amdahl where the
GNU C-compiler was considered for use in development of Amdhal’s mainframe
implementation of UNIX. Most recently, he was responsible for drafting
the license for Open Source Vera at Synopsys. He is a member of the Silicon
Valley Chapter of LES and one of the organizers of the Winter Meeting’s
Workshop on Open Source Software that he coordinated with Michel Mellinger
through the LES Converged Communications Technologies HTS Working Group.
[back to top]
Jill Rusk
Ms. Rusk is a Director with Navigant Consulting Inc., where she specializes
in
intellectual asset consulting, including both intellectual asset management
and
intellectual property litigation services. Ms. Rusk provides companies with
various
analyses related to their intellectual assets, including knowledge management,
portfolio management, strategy, competitive analysis, evaluation, process
improvement, license compliance, technology commercialization/monetization,
system design, and dispute resolution. Ms. Rusk has also worked closely with
internal and external legal counsel in many different technical areas, including
intellectual property valuation, legal process reorganization, transfer pricing
considerations, and other specialized intellectual asset needs.
[back to top]
Jonathan L. Schaffer, M.D., M.B.A.
At Cleveland Clinic, Dr. Schaffer is a managing director of eCleveland Clinic,
a state-of-the-art digital information system offering a variety of Internet-based
e-health services to patients around the globe. Clinically, Dr. Schaffer
is a staff member and Technology and Systems Chief in the Adult Reconstruction
Section and leads the Advanced Operative Technology Group in the Orthopaedic
Research Center. His clinical interests include the treatment of arthritic
knees and the application of new technologies in surgical care. He is
also a member of the Commercialization Council in Cleveland Clinic Innovations.
Dr. Schaffer is a graduate of Case Western Reserve University School of Medicine
and completed his residency in orthopaedic surgery at the University of Pennsylvania. He
completed fellowships in adult reconstruction at the Brigham and Women's Hospital
and Harvard Medical School and in research at Children's Hospital of Boston
and Harvard Medical School. Dr. Schaffer also holds a Master's in Business
Administration from the Kellogg Graduate School of Management at Northwestern
University.
[back to top]
Alex Scott
Alex Scott serves as Vice President of Business Development at Eisai Inc.
and oversees all business development activities, targeting opportunities
in Eisai's three areas of therapeutic focus – neurology, gastrointestinal
disorders, and oncology/critical care. Since the company's inception
in 1995, Eisai Inc. has grown from 25 employees to more than 1,300 employees,
with sales of approximately $2.2 billion in fiscal year 2005. Mr. Scott
has been instrumental in crafting Eisai's globalization strategy, establishing
commercial infrastructure, and negotiating global alliances with Pfizer and
Janssen for Aricept (donepezil
hydrochloride tablets) and Aciphex®/Pariet® (rabeprazole sodium)
tablets, respectively. Both Aricept® and Aciphex/Pariet® were
discovered and developed by Eisai. In addition, he has played a key
role in the successful conclusion of deals with Novartis for rufinamide, Elan
for Zonegran® (zonisamide) capsules, Dainippon for AS-3201, Pfizer for
an anti-coagulant and, most recently, Ligand for four oncology-related products.
Mr. Scott joined Eisai in 1992 as Manager of Corporate Affairs at Eisai Corporation
of North America. Before assuming his current role, he held several positions
of increasing responsibility in Corporate Affairs, Planning and Business Development
within Eisai U.S. operations.
[back to top]
Howard Skaist
Howard Skaist was formerly the Director of Patents at Intel Corporation. In
2003, he founded Berkeley Law and Technology Group, LLP (BLTG). With
a total of sixteen lawyers, BLTG is based in Oregon and handles all aspects
of intellectual property practice, including: patent preparation and prosecution,
patent strategy, portfolio building and management, patent assertion and other
patent license negotiation support, preparing patent opinion letters, and strategic
oversight of patent litigation.
[back to top]
Mike Slessor
Mike Slessor is the Assistant Director in the Office of Technology Transfer
at the California Institute of Technology (Caltech), a nonprofit university
that also administers the Jet Propulsion Laboratory (JPL) for NASA. In this
role, he is part of a team that manages the Caltech/JPL intellectual property
portfolio, which includes over 2500 issued and pending patents; directs
outside counsel in patent prosecution; and negotiates agreements to license intellectual
property to outside companies. He serves on the board of directors of Micromanipulator
Corporation, and on the advisory board of Microwave Bonding Instruments.
[back to top]
Jeff Snell
Jeff Snell, a Principal with CRA International, has extensive experience
valuing intellectual property in the context of licensing transactions, intellectual
property disputes, and litigation risk analysis. Mr. Snell has extensive
experience developing flexible valuation models to assist clients in negotiating
license agreements and in understanding the risks of potential damages claims
in intellectual property litigation.
[back to top]
Robert Vigil
Dr. Vigil specializes in the
application of economics and finance to intellectual property, antitrust,
and general commercial litigation damages-related matters. His work includes
assessment of damages in complex litigation cases, including analyses of
lost profits, reasonable royalties, price erosion, and unjust enrichment.
Dr. Vigil's
experience spans a wide variety of industries including pharmaceuticals,
medical devices, telecommunications, computer hardware and software, and
consumer products. In addition, Dr. Vigil has experience in technology valuation
and licensing strategy in prospective non-litigation licensing matters. He
has worked with inventors, corporations, and licensing experts to provide
analysis of the products and markets to which technologies may be applied.
He has also provided intellectual property owners with analysis of and recommendations
for the appropriate terms of technology transfer and performed prospective
market valuations of assorted intellectual property in an array of industries.
He has given presentations on intellectual property issues before professional
and academic groups.
[back to top]
Jason B. Wacha
Recognized by the San Francisco Daily Journal as "one of the country's
preeminent experts on open source software licensing, " and named as a
Northern California Super Lawyer® for 2006, Jason supervises MontaVista
Software's worldwide legal policies and practices, and develops and implements
the company's intellectual property strategy. Jason speaks nationally
and internationally, and is a published author on open source licensing and
the GPL. Jason also regularly lectures at law schools on both technology
licensing and international business transactions. He is a founder of
Open Bar (www.open-bar.org), and is
a contributing columnist to the Enterprise Open Source Journal. Jason
was previously a VP and General Counsel for Advanced Data Exchange, and also
practiced law with Wilson Sonsini Goodrich & Rosati.
[back to top]
Steven Weiner
Steven Weiner is a partner with Davis Polk & Wardwell, practicing in the
Menlo Park, California office and spearheading the firm's corporate intellectual
property (IP) practice. He has in-depth experience advising technology
and media companies and their stakeholders on business-critical IP matters, including:
analysis and evaluation of patent portfolios and claims; assessing, avoiding
and responding to third-party IP threats; enforcing and protecting valuable IP
assets; and negotiating IP asset transactions, including mergers and acquisitions,
license agreements, and joint technology development. His clients are a
diverse group of industry leaders and innovators, including Comcast, Yahoo!,
Affymetrix and Form Factor; leading investment firms and financial institutions;
and early-stage ventures and non-profits at the cutting edge of research and
development.
Steve joined Davis Polk in 2002 after serving as Vice President for Intellectual
Property and Strategic Planning at SRI International, an independent non-profit
research and development institute. He held senior responsibility for
growing and cultivating SRI's diverse portfolio of IP assets, and for exploiting
those assets through new ventures and license transactions. He also successfully
directed SRI's internal strategic investments in new technologies, stimulating
value creation and business growth. Before joining SRI, Steve was senior
intellectual property counsel at SGI, where he rapidly developed an aggressive
software patent portfolio that was subsequently sold to Microsoft for $60 million.
Prior to that he practiced for five years with Irell & Manella, focusing
on IP litigation and counseling, and was a member of the trial team that in
1994 successfully obtained a jury verdict of over $100 million in favor of
Stac Electronics against Microsoft based on software patent infringement.
[back to top]
Elaine F. White
Elaine White is the Associate Director for Technology Licensing at Boston
College, where she has lead responsiblity for intellectual property identification,
evaluation, protection and licensing. Prior to joining BC in late 2003,
she was a Technology Licensing Specialist in the NIH Office of Technology Transfer,
and subsequently an Industry Agreements Manager with Partners HealthCare/Massachusetts
General Hospital.
Elaine holds a Master's in Biology from UCLA and an M.B.A. in Finance
from New York University's Stern School of Business, where she was an
intern with Pfizer Inc. Prior to beginning her M.B.A. studies, she was
employed as a research biologist in the laboratories of Edward B. Lewis and
Leroy Hood at the California Institute of Technology.
[back to top]
William Zahrt
Currently a partner at Ishimaru & Zahrt LLP, Bill Zahrt has specialized in
technology and intellectual property law since 1969. He has extensive
corporate experience, most recently as Associate General Counsel and Legal Director,
Intellectual Property, at Palm, Inc., a leading worldwide provider of handheld
computers. At Palm he supervised and directed all IP and related legal
activities and functions, including licensing and litigation. Earlier,
he was Assistant General Counsel in the Technology Law Department of Advanced
Micro Devices, Senior Patent Counsel for Raychem Corporation, and held patent
attorney positions at Shell Oil Company and Schlumberger. He is licensed
by the U.S. Patent and Trademark Office, and the New York, Ohio, California,
Texas, and North Carolina Bar Associations.
[back to top] |
